MFDS Approves AbbVie's Migraine Prevention Drug 'Aqupta Tablets'
On the 15th, the Ministry of Food and Drug Safety announced the approval of the imported new drug from Korea AbbVie, 'Aqupta Tablets (active ingredient Atogepant)' 10mg and 60mg, used for migraine prevention.
Aqupta selectively blocks the calcitonin gene-related peptide (CGRP) receptor, a receptor that mediates intracellular signaling related to inflammation and immune responses, thereby preventing migraines. CGRP is known as a vasodilatory neurotransmitter that causes migraine headaches along with the dilation of the middle cerebral artery.
Hot Picks Today
Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- "Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "You Don't Need to Go to the Gym": The Best Exercises for Lowering Hypertension
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
Aqupta Tablets are the first oral CGRP antagonist developed with this mechanism and were previously approved by the U.S. Food and Drug Administration (FDA) in April and the European Medicines Agency (EMA) in August. The Ministry of Food and Drug Safety stated, "Aqupta Tablets are expected to help expand the options for migraine prevention drugs for adult migraine patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
